(101 days)
Not Found
Biostar Flu OIA
No
The device description details a qualitative immunoassay based on antibody-antigen binding and chromatographic migration, with no mention of computational analysis, algorithms, or learning processes.
No
The device is an in vitro diagnostic test designed to detect viral antigens for diagnosis and epidemiological purposes, not to treat a disease or condition.
Yes
The "Intended Use / Indications for Use" section explicitly states, "This test is intended for professional in vitro diagnostic use to aid in the diagnosis of Influenza infections."
No
The device description explicitly lists physical components such as swabs, reaction cups, test strips, and reagent solutions, indicating it is a hardware-based in vitro diagnostic test, not a software-only device.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use/Indications for Use: The very first sentence explicitly states, "This test is intended for professional in vitro diagnostic use..." This is the most direct indicator.
- Nature of the Test: The test is a "qualitative immunoassay for the rapid detection of Influenza A/B viral antigens from throat swab specimens." This describes a test performed on a biological sample (throat swab) outside of the body (in vitro) to diagnose a condition (Influenza).
- Purpose: The intended use is "to aid in the diagnosis of Influenza infections, and to gather epidemiological information for detection of Influenza outbreaks." This aligns with the purpose of IVD devices, which are used to provide information for diagnosis, monitoring, or screening.
- Device Description: The description details the components and mechanism of the test, which is designed to analyze a biological sample for the presence of specific markers (viral antigens).
- Intended User/Care Setting: It specifies "Professional in vitro diagnostic use," further reinforcing its classification as an IVD.
All of these points clearly indicate that the Influenza A/B Rapid Test is an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The Influenza A/B Rapid Test is a qualitative immunoassay for the rapid detection of Influenza A/B viral antigens from throat swab specimens. This test is intended for professional in vitro diagnostic use to aid in the diagnosis of Influenza infections, and to gather epidemiological information for detection of Influenza outbreaks. When used for diagnosis, negative assay results should be confirmed by cell culture. This assay does not detect the presence of Influenza C viral antigens.
Product codes
GNX
Device Description
The Influenza A/B Rapid Test consists of swabs, reaction cups, test strips, and reagent solutions. The test detects the viral nucleoprotein associated with the viral nucleic acid. The nucleoprotein is released by lysing the virus envelop with the lysis/elution solution. Since the nucleoprotein is type specific only (not subtype specific), the test uses two pairs of monoclonal antibodies – one pair is specific for Influenza A, the other is specific for Influenza B. The antibody pairs are conjugated to either biotin or digoxigenin. In the presence of the viral antigen, a sandwich complex is formed, consisting of the biotin-conjugated antibody, the nucleoprotein, and the digoxigenin-conjugated antibody. When the test strip is placed in the reaction cup, the complex migrates chromatographically, solubilizing colloidal gold particles incorporated in the red pad of the strip. The colloidal gold particles bind to the digoxigenin of the complex, which is then bound by the biotin to the immobilized streptavidin on the strip (positive result line). Any excess gold particles continue to migrate to the second line (control line), which then becomes visible. This indicates the correct chromatographic migration.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Throat
Indicated Patient Age Range
Not Found
Intended User / Care Setting
professional in vitro diagnostic use
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
standalone performance: Sensitivity 68.4% Specificity 80.7%
Key Metrics
Sensitivity 68.4%
Specificity 80.7%
Predicate Device(s)
Biostar Flu OIA
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 866.3328 Influenza virus antigen detection test system.
(a)
Identification. An influenza virus antigen detection test system is a device intended for the qualitative detection of influenza viral antigens directly from clinical specimens in patients with signs and symptoms of respiratory infection. The test aids in the diagnosis of influenza infection and provides epidemiological information on influenza. Due to the propensity of the virus to mutate, new strains emerge over time which may potentially affect the performance of these devices. Because influenza is highly contagious and may lead to an acute respiratory tract infection causing severe illness and even death, the accuracy of these devices has serious public health implications.(b)
Classification. Class II (special controls). The special controls for this device are:(1) The device's sensitivity and specificity performance characteristics or positive percent agreement and negative percent agreement, for each specimen type claimed in the intended use of the device, must meet one of the following two minimum clinical performance criteria:
(i) For devices evaluated as compared to an FDA-cleared nucleic acid based-test or other currently appropriate and FDA accepted comparator method other than correctly performed viral culture method:
(A) The positive percent agreement estimate for the device when testing for influenza A and influenza B must be at the point estimate of at least 80 percent with a lower bound of the 95 percent confidence interval that is greater than or equal to 70 percent.
(B) The negative percent agreement estimate for the device when testing for influenza A and influenza B must be at the point estimate of at least 95 percent with a lower bound of the 95 percent confidence interval that is greater than or equal to 90 percent.
(ii) For devices evaluated as compared to correctly performed viral culture method as the comparator method:
(A) The sensitivity estimate for the device when testing for influenza A must be at the point estimate of at least 90 percent with a lower bound of the 95 percent confidence interval that is greater than or equal to 80 percent. The sensitivity estimate for the device when testing for influenza B must be at the point estimate of at least 80 percent with a lower bound of the 95 percent confidence interval that is greater than or equal to 70 percent.
(B) The specificity estimate for the device when testing for influenza A and influenza B must be at the point estimate of at least 95 percent with a lower bound of the 95 percent confidence interval that is greater than or equal to 90 percent.
(2) When performing testing to demonstrate the device meets the requirements in paragraph (b)(1) of this section, a currently appropriate and FDA accepted comparator method must be used to establish assay performance in clinical studies.
(3) Annual analytical reactivity testing of the device must be performed with contemporary influenza strains. This annual analytical reactivity testing must meet the following criteria:
(i) The appropriate strains to be tested will be identified by FDA in consultation with the Centers for Disease Control and Prevention (CDC) and sourced from CDC or an FDA-designated source. If the annual strains are not available from CDC, FDA will identify an alternative source for obtaining the requisite strains.
(ii) The testing must be conducted according to a standardized protocol considered and determined by FDA to be acceptable and appropriate.
(iii) By July 31 of each calendar year, the results of the last 3 years of annual analytical reactivity testing must be included as part of the device's labeling. If a device has not been on the market long enough for 3 years of annual analytical reactivity testing to have been conducted since the device received marketing authorization from FDA, then the results of every annual analytical reactivity testing since the device received marketing authorization from FDA must be included. The results must be presented as part of the device's labeling in a tabular format, which includes the detailed information for each virus tested as described in the certificate of authentication, either by:
(A) Placing the results directly in the device's § 809.10(b) of this chapter compliant labeling that physically accompanies the device in a separate section of the labeling where the analytical reactivity testing data can be found; or
(B) In the device's label or in other labeling that physically accompanies the device, prominently providing a hyperlink to the manufacturer's public Web site where the analytical reactivity testing data can be found. The manufacturer's home page, as well as the primary part of the manufacturer's Web site that discusses the device, must provide a prominently placed hyperlink to the Web page containing this information and must allow unrestricted viewing access.
(4) If one of the actions listed at section 564(b)(1)(A)-(D) of the Federal Food, Drug, and Cosmetic Act occurs with respect to an influenza viral strain, or if the Secretary of Health and Human Services (HHS) determines, under section 319(a) of the Public Health Service Act, that a disease or disorder presents a public health emergency, or that a public health emergency otherwise exists, with respect to an influenza viral strain:
(i) Within 30 days from the date that FDA notifies manufacturers that characterized viral samples are available for test evaluation, the manufacturer must have testing performed on the device with those viral samples in accordance with a standardized protocol considered and determined by FDA to be acceptable and appropriate. The procedure and location of testing may depend on the nature of the emerging virus.
(ii) Within 60 days from the date that FDA notifies manufacturers that characterized viral samples are available for test evaluation and continuing until 3 years from that date, the results of the influenza emergency analytical reactivity testing, including the detailed information for the virus tested as described in the certificate of authentication, must be included as part of the device's labeling in a tabular format, either by:
(A) Placing the results directly in the device's § 809.10(b) of this chapter compliant labeling that physically accompanies the device in a separate section of the labeling where analytical reactivity testing data can be found, but separate from the annual analytical reactivity testing results; or
(B) In a section of the device's label or in other labeling that physically accompanies the device, prominently providing a hyperlink to the manufacturer's public Web site where the analytical reactivity testing data can be found. The manufacturer's home page, as well as the primary part of the manufacturer's Web site that discusses the device, must provide a prominently placed hyperlink to the Web page containing this information and must allow unrestricted viewing access.
0
| 510(k) Summary | |
|---|---|
| Introduction | According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence. |
| 1) Submitter name, address, contact | Roche Diagnostics Corporation |
| 9115 Hague Rd. | |
| Indianapolis, IN 46250 | |
| (317) 845-2000 |
Contact Person: Luann Ochs
Date Prepared: September 8, 1999. |
| 2) Device name | Proprietary name: Roche Diagnostics Influenza A/B Rapid Test
Common name: Influenza virus detection reagents
Classification name: Antigens, CF (including CF control), influenza virus A, B, C |
| 3) Predicate device | We claim substantial equivalence to the Biostar Flu OIA, optical immunoassay for the rapid detection of influenza A and B. |
Continued on next page### 510(k) Summarv
1
510(k) Summary, Continued
| 4) Device
Description | The Influenza A/B Rapid Test consists of swabs, reaction cups, test strips,
and reagent solutions. |
|--------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | The test detects the viral nucleoprotein associated with the viral nucleic acid.
The nucleoprotein is released by lysing the virus envelop with the
lysis/elution solution. Since the nucleoprotein is type specific only (not
subtype specific), the test uses two pairs of monoclonal antibodies – one pair
is specific for Influenza A, the other is specific for Influenza B. The antibody
pairs are conjugated to either biotin or digoxigenin. |
| | In the presence of the viral antigen, a sandwich complex is formed, consisting
of the biotin-conjugated antibody, the nucleoprotein, and the digoxigenin-
conjugated antibody. When the test strip is placed in the reaction cup, the
complex migrates chromatographically, solubilizing colloidal gold particles
incorporated in the red pad of the strip. The colloidal gold particles bind to the
digoxigenin of the complex, which is then bound by the biotin to the
immobilized streptavidin on the strip (positive result line). Any excess gold
particles continue to migrate to the second line (control line), which then
becomes visible. This indicates the correct chromatographic migration. |
| 5) Intended use | The Influenza A/B Rapid Test is a qualitative immunoassay for the rapid
detection of Influenza A/B viral antigens from throat swab specimens. This
test is intended for professional in vitro diagnostic use to aid in the diagnosis
of Influenza infections, and to gather epidemiological information for
detection of Influenza outbreaks. When used for diagnosis, negative assay
results should be confirmed by cell culture. This assay does not detect the
presence of Influenza C viral antigens. |
2
510(k) Summary, Continued
- Comparison to predicate device
The Roche Diagnostics Influenza A/B Rapid Test is substantially equivalent to other products in commercial distribution intended for similar use. Most notably it is substantially equivalent to the currently marketed Biostar Flu AB OIA.
| Feature | RDC Influenza A/B Rapid Test | Biostar Flu OIA |
|---|---|---|
| Intended use | Detection of Influenza A and B viral antigen | Detection of Influenza A and B viral antigen |
| Indication for use | Aid in the diagnosis of influenza A or B viral infections. | Aid in the diagnosis of influenza A or B viral infections. |
| Sample type | Throat swab | Throat swab, nasal aspirate, nasopharyngeal swab, or sputum. |
| Test Principle | Direct visualization of antigen-antibody complex binding to a surface. | Direct visualization of antigen-antibody complex binding to a surface. |
| Results | Positive or negative qualitative results | Positive or negative qualitative results |
| Quality control | Internal procedural quality control, external quality control solutions | Internal procedural quality control, external quality control solutions |
| Performance | Sensitivity 68.4% | |
| Specificity 80.7% | Sensitivity 62% | |
| Specificity 80% |
Continued on next page
3
510(k) Summary, Continued
6) Comparison to predicate device, continued
Differences
| Feature | RDC Influenza A/B
Rapid Test | Biostar Flu OIA |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Procedure | Rapid, simple procedure:
- Extract sample in solution for 1 minute.
- Add antibody reagents and mix.
- Place test strip in solution.
- Read results after 10 minutes. | Complicated, long procedure:
- Extract sample in solution for 3 minutes. Add reagent.
- Pipet one drop of sample onto test surface. Wait 6 minutes.
- Wash the test surface.
- Blot the test surface.
- Add substrate reagent. Wait 6 minutes.
- Wash the test surface.
- Blot test surface.
- Read results. |
| Total Assay Time | 12 minutes | 20 minutes |
| Incubation Time | 10 minutes | 15 minutes |
Benefits:
The RDC Influenza A/B Rapid Test is easier to perform than the Biostar Flu OIA. The Influenza A/B Rapid Test has fewer procedural steps, and can be completed in about 12 minutes, versus about 20 minutes for the Biostar Flu OIA. Both tests utilize throat swab specimens, and contain antibodies to viral nucleoprotein for the detection of Influenza A or B.
4
Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circle with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized image of a human figure with three lines representing the body and head. The figure is facing to the right.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
DEC 2 0 1999
Mr. Luann Ochs Regulatory Program Manager Roche Diagnostics Corporation 9115 Hague Road Indianapolis. Indiana 46250-0457
Re: K993048 Trade Name: Roche Diagnostics Influenza A/B Rapid Test Regulatory Class: I Product Code: GNX Dated: November 9, 1999 Received: November 10, 1999
Dear Mr. Ochs:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic OS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
5
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770)488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number (800) 638-2041 or at (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html"
Sincerely yours,
Steven Butman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
6
510(k) Number (if known): Device Name: Roche Diagnostics Influenza A/B Rapid Test Indications for Use:
The Influenza A/B Rapid Test is a qualitative immunoassay for the rapid detection of Influenza A/B viral antigens from throat swab specimens. This test is intended for professional in vitro diagnostic use to aid in the diagnosis of Influenza infections, and to gather epidemiological information for detection of Influenza outbreaks. When used for diagnosis, negative assay results should be confirmed by cell culture. This assay does not detect the presence of Influenza C viral antigens.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Woody Dubois
(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number K993048
Prescription Use (Per 21 CFR 801.109)
OR
Over-The-Counter Use
(Optional Format 1-2-96)